

## Biomedical Catalyst Awards

The tables below indicate the awards made by MRC and Innovate UK under the Biomedical Catalyst scheme.

- Further details, including the abstract, can be found on the Gateway to research website <http://gtr.rcuk.ac.uk/>

### Round 1

Award Type	Lead Organisation	Location	Grant Value (£)*	Project Value (£)**	Project Duration (months)	Project Title	Additional grant awardees (SME-led awards only)
Feasibility (Confidence in Concept)	University of Birmingham	Birmingham	£600,000	£600,000	18	ProTG: Project Translational Groups to enhance further development of fundamental science in Birmingham	
Feasibility (Confidence in Concept)	University of Cambridge	Cambridge	£750,000	£750,000	18	Cambridge Confidence in Concepts: Translation of Pathophysiological Insights in to New Therapies	
Feasibility (Confidence in Concept)	University of Dundee	Dundee	£700,000	£700,000	18	The Innovative Targets Portfolio: Basic Life Sciences Research to Novel Therapies, through a Portfolio of Small Molecule Translational Projects	
Feasibility (Confidence in Concept)	University of Edinburgh	Edinburgh	£700,000	£700,000	18	Confidence in Concept CMVM University of Edinburgh - Edinburgh Partners Devices and Diagnostics (EPDD)	
Feasibility (Confidence in Concept)	Imperial College London	London	£500,000	£500,000	18	"ICIC": The Imperial Confidence in Concept Fund	
Feasibility (Confidence in Concept)	King's College London	London	£250,000	£250,000	18	Establishing a rapid and flexible early stage translation pathway for King's Health Partners	
Feasibility (Confidence in Concept)	Liverpool School of Tropical Medicine	Liverpool	£400,000	£400,000	18	Accelerating Product Development for Tropical Infectious Disease	
Feasibility (Confidence in Concept)	The University of Manchester	Manchester	£750,000	£750,000	18	The University of Manchester bid to the MRC Confidence in Concept Scheme	
Feasibility (Confidence in Concept)	University of Nottingham	Nottingham	£300,000	£300,000	18	Realising the potential healthcare benefits of novel biomedical research concepts and discoveries at The University of Nottingham.	
Feasibility (Confidence in Concept)	University of Oxford	Oxford	£600,000	£600,000	18	The Oxford MRC Confidence in Concept Partnership	

Feasibility (Confidence in Concept)	Queen's University Belfast	Belfast	£500,000	£500,000	18	Queen's Confidence in Concept (CIC) Awards: Improving and accelerating translational medical research towards clinical benefit	
Feasibility (Confidence in Concept)	University of Sheffield	Sheffield	£360,000	£360,000	18	Addressing the funding gap to advance early stage healthcare research at the University of Sheffield	
Feasibility (Confidence in Concept)	University of Strathclyde	Glasgow	£300,000	£300,000	18	Maximising Translational Durability	
Feasibility (Confidence in Concept)	University College London	London	£700,000	£700,000	18	The MRC Confidence in Concepts at UCL Fund	
Feasibility	Roslin Cells Ltd.	Edinburgh	£125,738	£167,651	12	Improving the Clinical Utility of Umbilical Cord Blood Donations by Ex-Vivo Expansion Using Mesenchymal Stromal Cells	
Feasibility	Sentinel Oncology Limited	Cambridge	£149,508	£199,344	10	Novel first in class p70S6 kinase inhibitors: Definition of clinical development path	
Feasibility	Endomagntics Ltd	Cambridge	£134,224	£171,511	9	Feasibility and market potential for expanding the SentiMag indication to sentinel lymph node biopsy in melanoma	Kings College London
Feasibility	Intelligent Fingerprinting Limited	Norwich	£136,418	£181,891	12	Feasibility of a hand-held, non-invasive IVD device to detect the presence of drugs in A&E admissions from fingerprints	
Feasibility	Absynth Biologics Limited	Sheffield	£150,000	£201,103	12	BUILDING A PRODUCT PIPELINE – ESTABLISHING THE COMMERCIAL POTENTIAL OF NEW PRODUCTS	
Feasibility	Summit Corporation plc	Oxford	£150,000	£205,019	8	Development of novel drugs for Alzheimer's disease using Summit's Seglin technology	
Feasibility	Haemaflow Limited	Swansea	£102,000	£136,682	12	Improving Blood Transfusion	
Feasibility	Xiros Ltd	Leeds	£150,000	£216,420	12	Wound Care Fibre	
Feasibility	BioMoti Ltd	London	£150,000	£203,251	12	MOT11001: Oncojan based drug candidate for the treatment of ovarian cancer	
Feasibility	iMonSys Ltd	York	£127,170	£181,086	12	Multi functional medical ear sensor	University of Hull; Triteq Ltd
Feasibility	Pharmidex Pharmaceutical Services Ltd	London	£149,634	£199,512	8	Identifying novel brain active molecules: Developing an integrated bioengineering & in silico screening platform technology (IBIS)	Hypha Discovery Ltd
Feasibility	Domainex Limited	Cambridge	£150,000	£200,004	12	Proving the feasibility of IKKe inhibitors as therapeutics for treatment of Chronic Obstructive Pulmonary Disease (COPD)	

Feasibility	GeneFirst Ltd	Oxford	£113,197	£150,930	12	Multiplex sensitive type-specific detection of all 14 high-risk HPV strains in a single closed-tube reaction	
Feasibility	Union Life Sciences Ltd	London	£150,000	£262,936	12	Novel inhibitors for the treatment of infectious disease	University of Sheffield
Feasibility	PhotoBiotics Ltd	London	£94,200	£125,600	12	OptiLinked Antibody Drug Conjugates for Cancer Therapy	
Feasibility	BluTest Laboratories Ltd.	Glasgow	£150,000	£200,000	12	Feasibility of a rapid, sensitive, nucleic acid based test for detection and serotyping of enteric viruses of human health importance	DestiNA Genomics Ltd
Feasibility	Opal Oncology Limited	Cambridge	£150,000	£200,286	12	IKKb Inhibitor Proposal	
Feasibility	MapMyHealth Limited	Nottingham	£117,277	£156,370	8	Assessment of the feasibility of a comprehensive web-based system for patient self-management in Type 2 Diabetes	
Early	Sarah Gilbert - University of Oxford	Oxford	£798,051	£798,051	36	Clinical assessment of a novel simian adenovirus-vectored influenza vaccine designed to induce broadly protective immunity	
Early	Hubert Gaspar - University College London	London	£1,222,698	£1,222,698	60	Phase I/II trial of lentiviral vector mediated gene therapy for Adenosine Deaminase deficiency	
Early	Stephen Howie - MRC Unit, The Gambia	Gambia	£988,005	£988,005	30	Novel oxygen solutions to prevent child pneumonia deaths	
Early	Nicola Sibson - University of Oxford	Oxford	£2,563,579	£2,563,579	36	Novel targeted contrast agent for early detection of brain metastasis: from animal to patient stage 2	
Early	Simon Cutting - Royal Holloway, University of London	London	£503,376	£827,376	24	Development of a Clostridium difficile Vaccine	
Early	Sarah Thomas - Kings College London	London	£677,344	£677,344	30	NANOHAT: Development of a safer and more effective sleeping sickness drug.	
Early	Elizabeth Shephard - University College London	London	£357,949	£867,949	24	Therapy for the body and breath malodour disorder Trimethylaminuria (TMAU)	
Early	Helen Curran - University College London	London	£987,825	£987,825	45	Cannabidiol: a novel treatment for cannabis dependence?	
Early	Barry Wright - Leeds & York Partnership NHS Fdn Trust	Leeds	£472,678	£472,678	42	DIADS - Diagnostic Instruments for Autism in Deaf Children Study	
Early	Shon Lewis - The University of Manchester	Manchester	£894,769	£974,769	30	Personalised monitoring and enhanced self-management in mental health (CareLoop)	

Early	Kalvista Pharmaceuticals Ltd	Salisbury	£2,400,000	£4,912,569	36	Pre-clinical development of novel oral plasma kallikrein inhibitors for the treatment of diabetic macular edema	
Early	Cyclacel Ltd	Dundee	£1,162,696	£1,937,828	26	First-In-Man' directed pre-clinical development of an anti-cancer agent - CYC065	
Early	Discuva Ltd	Cambridge	£1,620,000	£2,700,000	24	Discovery of New Commercially Valuable Antibiotics to Treat Bacterial Infection	
Early	IXICO Ltd.	London	£2,155,119	£3,362,197	36	Digital Healthcare Platform for Early Dementia Diagnosis	Imperial College London; University of Sussex; Cambridge Cognition Ltd; King's College London
Early	UB Pharma	Edinburgh	£1,997,840	£3,995,681	36	Preclinical development of ubiquitin E3 ligase inhibitors for prostate and breast cancer	
Early	Prosonix Limited	Oxford	£1,298,314	£2,596,644	18	Smart Combination Respiratory Medicines for Optimal & Cost Effective Patient Benefit	Imperial College London; University of Bath
Early	Intelligent Fingerprinting Limited	Norwich	£288,437	£576,874	24	Non-invasive Testing for Drugs in Fingerprints to Address an Unmet Need of Coroners	
Early	Cantab Biopharmaceuticals Limited	Welwyn Garden City	£2,321,884	£3,869,807	30	Addressing MDR Gram-negative bacterial infections by enhanced antibiotic uptake	
Early	Arecor Ltd	Cambridge	£785,418	£1,309,031	24	Novel excipients to allow superior liquid antibody formulation at high concentration	
Early	Medical Research Council Technology Ltd	London	£577,853	£1,155,706	36	A therapeutic anti-IL16 antibody for the treatment of Ischaemic Reperfusion Injury	
Early	ImmunoBiology Ltd	Cambridge	£490,000	£980,196	12	Development of a Universal Meningococcal Vaccine	
Early	OJ-Bio Ltd	Newcastle-upon-tyne	£632,073	£1,053,455	24	VIRASENS 2 - Pilot manufacture product for rapid detection of respiratory viruses	
Early	Pharminox Ltd	Nottingham	£484,096	£807,000	18	The discovery and optimisation of novel drugs to treat temozolomide-resistant glioma	
Early	ELISHA Systems Ltd	Leeds	£358,956	£717,956	30	Phage lysin biosensor detection of MRSA: point of care prototype: PROMPT-Plus	Leeds Teaching Hospital NHS Trust; Food and Environment Research Agency
Early	Sentinel Oncology Limited	Cambridge	£1,786,182	£2,976,971	24	Development of an Investigational New Drug for the treatment of pancreatic cancer	
Early	Modern Biosciences plc	London	£1,562,595	£2,845,008	26	Novel, oral anti-inflammatory compounds for the treatment of rheumatoid arthritis	

Early	Glide Pharmaceutical Technologies Ltd	Abingdon	£2,287,895	£3,813,159	30	Novel Teriparatide (PTH) Formulation	
Late	PsiOxus Therapeutics Ltd	Abingdon	£1,707,687	£3,435,374	26	OCTAVE - Ovarian Cancer Trial with an Enhanced Group B Oncolytic Adenovirus	
Late	Creabilis Ltd	Canterbury	£1,422,910	£2,372,518	15	Clinical Development of CT327, a novel treatment for childhood Atopic Dermatitis	
Late	Bioinduction Limited	Bristol	£447,784	£762,973	24	Improvements in neuromodulation for late-stage Parkinson's disease	
Late	Immunocore Limited	Abingdon	£2,400,000	£4,999,393	36	Clinical development of a new targeted therapy for the treatment of prostate cancer	
Late	QuantuMDx Group Limited	Newcastle	£1,419,621	£2,839,242	36	Q-CANCER: development of a sample to result device for low cost, rapid tumour profiling	Magna Parva Ltd; Leaders in Oncology Care Ltd; Newcastle University

Round 2

Award Type	Lead Organisation	Location	Grant Value (£) *	Project Value (£) **	Project Duration (months)	Project Title	Additional grant awardees (SME-led awards only)
Feasibility	ImmunoBiology Ltd (ImmBio)	Cambridge	£147,000	£198,130	12	Low cost, broadly efficacious Pneumococcal vaccine	
Feasibility	Domainex Limited	Cambridge	£150,000	£205,104	12	Proving the feasibility of using SMYD3 inhibitors as therapeutics for treatment of hepatocellular carcinoma and other cancers.	
Feasibility	Applied Nanodetectors Ltd	Enfield	£149,709	£199,612	12	Point of care exhaled breath test for the diagnosis of community acquired pneumonia	
Feasibility	Xention Limited	Pampisford	£143,900	£191,930	12	TRPA1 hit expansion and validation	
Feasibility	Expioristics Ltd	Ballynahinch (NI)	£79,000	£105,454	7.5	Feasibility study for the development of a software platform for the design of stratified medicine and benefit-risk studies.	
Feasibility	Neuregenix Ltd	Birmingham	£110,500	£147,938	12	Formulation of a novel siRNA drug to treat glaucoma	
Feasibility	Cambimune Ltd	Fulbourn	£113,178	£150,904	12	Feasibility of applying a novel virus like particle technology to an innovative RSV vaccine .	
Feasibility	Integrated Magnetic Systems Ltd	Dundee	£150,000	£217,826	12	Magnetic Antibodies in Point-of-Care Diagnostics	
Feasibility	Peptinnovate Limited	Stevenage	£150,000	£200,595	9	Exploration and exploitation of a unique anti-inflammatory pathway derived from M.tuberculosis proteins	
Feasibility	Immune Targeting Systems (ITS) Ltd	London	£150,000	£267,662	12	Feasibility assessment of a novel vaccine platform for the stratified therapeutic vaccine intervention in non-small cell lung cancer.	
Feasibility	CRDM Ltd	High Wycombe	£150,000	£227,283	10	The Feasibility of Manufacturing Titanium Alloy Intramedullary Nails Economically with Enhanced Design Freedom (I-NEED)	University College London
Feasibility	The Native Antigen Company Ltd	Upper Heyford	£109,828	£146,438	12	A novel virus-like particle based mammalian expression system targeted at vaccine development against envelope viruses.	
Feasibility	ProteinLogic Ltd	Cambridge	£76,922	£102,562	9	Feasibility of developing a novel biomarker signature as an innovative diagnostic for tuberculosis (TB)	

Feasibility	Cirridian Medical Limited	Cambridge	£142,175	£189,569	7	Implantable continuous glucose monitor using an optical reflection grating	
Feasibility	Indigix Ltd	Oxford	£150,000	£200,000	12	Dendrimer based drug for life threatening infectious diarrhoeal diseases	
Feasibility	F-star Biotechnology Ltd	Cambridge	£150,000	£260,033	10	DEVELOPMENT FEASIBILITY OF A NOVEL SUPERIOR HER2-SPECIFIC TARGETED DRUG CONJUGATE FOR CANCER THERAPY	
Feasibility	Stabilitech Ltd	London	£150,000	£206,369	12	Formulation of VZV to protect virus during manufacture and generate a thermo-stable vaccine to ensure market supply	
Feasibility	Imagen Biotech	Manchester	£42,286	£56,381	6	The use of High Content Phenotypic screening to guide the clinical management of cancer treatment.	
Feasibility	MISSION Therapeutics Ltd	Cambridge	£144,030	£194,030	12	Identifying deubiquitylating enzymes (DUBs) as targets for treating of platinum-resistant ovarian cancer	
Feasibility	Team Consulting Limited	Ickleton	£89,800	£119,700	6	Occoris Inhaler Engine Development	
Feasibility	Enigma Diagnostics Ltd	Porton Down	£148,338	£197,785	4	Resonant sensing, a novel form of DNA detection for low-cost highly informative tests; construction of an assay for multidrug resistant TB and bovine TB	
Feasibility	XenoGesis Limited	Nottingham	£148,509	£198,012	12	Evaluation of membrane-retentive pro-drugs to increase duration of effect to enable once-a-day dosing of inhaled muscarinic M3 receptor antagonists	University of Nottingham
Feasibility	Pathology Diagnostics Ltd.	Cambridge	£142,629	£190,173	12	Feasibility study of TRANSPATH: novel software technology platforms for tissue biomarker quantitation for stratified medicine & oncology drug development	
Feasibility	Gentronix Ltd	Manchester	£147,552	£196,736	12	Assessment of the feasibility of developing an in vitro screen for epigenetic mutagens	
Feasibility	Glide Pharmaceutical Technologies Ltd	Abingdon	£150,000	£201,211	12	Room temperature stable solid vaccine formulations suitable for needle free delivery	
Early	CellCentric Ltd	Cambridge	£2,200,000	£4,290,443	27	Novel drug candidates for the treatment of castrate resistant prostate cancer	
Early	Panion Ltd	Cambridge	£2,400,000	£4,739,933	36	Discovery of P2Y14 antagonists for the treatment of osteoarthritic pain	
Early	Autifony Therapeutics Limited	London	£1,940,438	£2,777,317	24	Development of a Kv3 Positive Modulator for the treatment of Schizophrenia	The University of Manchester; Newcastle University
Early	PhotoBiotics Ltd	London	£645,665	£785,918	24	Antibody Directed Phototherapy for Oesophageal Adenocarcinoma	University College London; Imperial College London

Early	Oxford BioTherapeutics Limited	Abingdon	£2,280,334	£5,374,257	36	Development of an Antibody Drug Conjugate for the Treatment of Pancreatic Cancer	Spirogen Limited
Early	Base4 Innovation Ltd	Cambridge	£2,250,000	£7,214,060	36	A rapid, highly sensitive, adaptable diagnostic for broad spectrum pathogen screening	
Early	Immune Targeting Systems (ITS) Ltd	London	£2,025,097	£3,375,161	18	Pre-Clinical Development of a Novel Therapeutic Vaccine for Chronic Hepatitis B	
Early	Calon Cardio-Technology Ltd	Swansea	£1,665,415	£2,585,680	24	Demonstration of a low cost implantable blood pump	Institute of Life Science, Swansea University
Early	Cyclacel Limited	Dundee	£2,264,482	£3,774,137	36	'First-In-Human' directed pre-clinical development of anti-cancer agent CYC140	
Early	Discion Ltd	Cambridge	£2,400,000	£4,990,207	36	Discovery of Ask1 inhibitors for the treatment of chronic neuropathic pain	
Early	ReNeuron Ltd	Guildford	£839,860	£1,166,487	18	Retinal Progenitor Cell Therapy Product for Ocular Disease	Institute of Ophthalmology, University College London
Early	Radius Diagnostics Ltd	Harwell	£570,000	£961,176	18	Flat panel X-ray source for Highly Portable 3D Planar X-ray Solution	
Early	Professor Giovanna Lombardi - King's College London	London	£1,990,730	£1,990,730	60	ThRIL: A 'first-in-human' study, evaluating the safety, tolerability with an investigation into the efficacy of Tregs in liver transplant recipients	
Early	Professor John Alan Goodacre - Lancaster University	Lancaster	£397,745	£397,745	24	Acoustic Emission as a non-invasive biomarker for quantitative dynamic assessment of knee joint repair in clinical trials and stratified medicine	
Early	Dr Quentin Bickle - London School of Hygiene and Tropical Medicine	London	£1,498,940	£1,498,940	42	Identification of a novel oral clinical candidate superior to praziquantel to treat schistosomiasis	
Early	Dr Bridget Bax - St George's, University of London	London	£3,107,927	£6,428,927	60	MICA: Clinical development of erythrocyte encapsulated thymidine phosphorylase - a therapy for mitochondrial neurogastrointestinal encephalomyopathy	
Early	Professor Ross Boyle - University of Hull	Hull	£644,360	£1,094,360	30	MICA: Well-characterised monoclonal antibody-photosensitiser conjugates for the treatment of head and neck cancer	
Early	Dr Simon Draper - University of Oxford	Oxford	£1,261,999	£1,405,999	36	MICA: Development and GMP manufacture of a PFRH5 protein vaccine to induce strain-transcending immunity against blood-stage Plasmodium falciparum.	
Late	Sky Medical Technology Limited	High Wycombe	£870,438	£1,450,731	24	A new approach for preventing DVT in THR post-operative patients using NMES	
Late	ReNeuron Limited	Guildford	£393,284	£655,473	24	A Phase I Safety Study of Intramuscular CTX0E03 in Lower Limb Ischaemic Patients	



Late	OrganOx Limited	Oxford	£2,400,000	£4,048,142	36	OrganOx Phase 2 Clinical Investigation	
Late	Canbex Therapeutics Ltd	London	£1,282,018	£1,948,847	18	Drug product production, clinical support studies, and phase 1 trial of a new MS drug	University College London; Queen Mary, University of London
Late	Atlantic Healthcare Limited	Saffron Walden	£1,890,410	£5,401,171	32	Phase III programme for alicaforsen enema in the orphan disease pouchitis	
Late	Atopix Therapeutics Limited	Oxford	£1,753,000	£2,962,555	18	Clinical utility of a CRTH2 antagonist, OC000459, as an anti-Th2 therapy in atopic dermatitis	
Late	Professor Robin Ali - University College London	London	£2,127,811	£2,127,811	60	Clinical trial of gene therapy for the treatment of achromatopsia	
Late	Professor Martin Birchall - University College London	London	£2,831,322	£2,831,322	50	RegenVOX: phase I/II clinical trial of stem cell based tissue engineered laryngeal implants	

Round 3

Award Type	Lead Organisation	Location	Grant Value (£) *	Project Value (£) **	Project Duration (months)	Project Title	Additional grant awardees (SME-led awards only)
Feasibility	Roslin Cellab Ltd	Edinburgh	£117,432	£156,576	12	Use of a Novel Cell Printer to Create, Analyse and Optimise 3D Liver Tissues	
Feasibility	Proveca Ltd	Daresbury	£143,090	£190,786	11	Novel age appropriate oral liquid formulation of tacrolimus	
Feasibility	iQur Ltd	London	£108,911	£175,649	12	Development of a novel VLP based vaccine for malaria	University of Oxford
Feasibility	Physiomics plc	Oxford	£150,000	£215,546	9	Clinical version of the Physiomics Virtual Tumour	
Feasibility	Moor Instruments Ltd	Axminster	£146,553	£195,405	12	Video Rate Blood Flow Imaging for Reconstructive Plastic Surgery	University of Exeter
Feasibility	Asymptote Ltd	Cambridge	£111,510	£148,680	12	Improved method of freeze drying	
Feasibility	Firstkind Limited	High Wycombe	£131,656	£175,542	9	Maintenance of functional capacity during lower limb immobilization and the potential for soft tissue repair for a novel form of neuromuscular electrostimulation	
Feasibility	Sareum Ltd	Cambridge	£148,377	£197,837	6	SAR studies to validate novel Fatty Acid Synthase (FASN) inhibitors as anti-cancer therapeutics	
Feasibility	Owlstone Ltd	Cambridge	£146,583	£195,447	9	Non-invasive identification and monitoring of Inflammatory Bowel Disease (IBD)	University of Warwick
Feasibility	Vodus Medical	Liverpool	£116,670	£155,560	12	Optical and Drug Techniques in reducing Urinary Catheter Blockages	University of Central Lancashire
Feasibility	IXICO Ltd.	London	£149,990	£199,991	12	Imaging Informatics for Early Diagnosis of Dementia in Chinese Elderly Population	
Feasibility	Intercytex Ltd	Manchester	£150,000	£200,000	12	Feasibility of developing innovative processes to improve the manufacturing logistics of cell therapy	
Feasibility	Valevia UK	Newbury	£150,000	£204,353	10	A Novel agent for the treatment of CDifficile infection	

Feasibility	Ai2 Ltd	Manchester	£150,000	£205,491	12	Assessing the feasibility of developing Ai2's novel anti-infective peptide technology for topical anti-fungal applications.	
Feasibility	Plasticell Limited	Stevenage	£149,600	£199,500	12	Brown adipose tissue cell therapy for obesity and diabetes	
Feasibility	Blueberry Therapeutics Ltd	Manchester	£150,000	£213,944	12	Development of a new class of bacterial resistance inhibitors for the treatment of multi-drug resistant infection	
Feasibility	GEM Nutrition Ltd	Daresbury	£26,688	£35,585	6	Optimum Weight Loss (OWL)	
Early	Arachos Pharma Ltd	Stevenage	£1,170,477	£1,950,796	18	Preclinical development of novel oral anti-inflammatory medicine AP362	
Early	JRI Orthopaedics Ltd	Sheffield	£391,296	£652,159	24	Early Stage Regenerative Remediation of hip OA by novel curvilinear arthroscopy	Surgical Innovations Limited
Early	Absynth Biologics Ltd	Sheffield	£2,013,706	£3,049,019	36	Staphylococcus aureus Infections - Development of A Novel, Effective Vaccine	University of Sheffield
Early	Chronos Therapeutics Ltd	Oxford	£548,790	£914,652	20	Pre-clinical proof of concept for a new agent in the treatment of ALS	
Early	The Automation Partnership (Cambridge)	Royston	£531,584	£695,016	18	Novel Engineered Living Neural Tissue, for Peripheral Nerve Repair	ReNeuron Plc; Open University
Early	Oxford Gene Technology Ltd	Oxford	£478,710	£664,626	18	A novel platform for targeted sequence enrichment prior to clinical NGS	University of Birmingham
Early	Oxford Immunotec Ltd	Oxford (Abingdon)	£167,200	£278,668	18	T cell assay for BK virus infection in transplant patients	
Early	Professor Timothy Cox - University of Cambridge	Cambridge	£2,268,966	£2,268,966	54	Gene Therapy for Tay-Sachs and Sandhoff diseases	
Early	Professor Anthony Gershlick - University of Leicester	Leicester	£384,904	£384,904	26	Studies in the development of a novel side-branch stent	
Early	Dr Sandra Bucci - The University of Manchester	Manchester	£425,259	£425,259	26	Active Assistance for Psychological Therapy (Actissist): Software to improve access and adherence to CBT targeting key relapse indicators in psychosis	
Early	Dr Sarah Fidler - Imperial College London	London	£1,595,718	£1,595,718	43	REACH: Recent HIV infection: Eradication by Activation of the HIV reservoir: A proof of concept trial towards a Cure for HIV.	
Late	MicroPharm Ltd	Newcastle Emllyn	£2,067,535	£2,599,535	36	Use of Ovine Polyclonal Antibodies to Treat Severe Clostridium difficile Infections	Public Health England; University of Leeds

Late	Summit Corporation plc	Abingdon, Oxford	£2,400,000	£8,254,278	30	Advancing utrophin modulator SMTc1100 into clinical proof of concept trials for DMD	
Late	Orthox Ltd	Abingdon, Oxford	£1,733,179	£3,421,339	36	Late stage development & clinical evaluation of FibroFix Cartilage: A Mechanically Functional, Tissue Regenerative, Knee Cartilage Repair Implant	
Late	Adaptimmune Ltd.	Abingdon, Oxford	£2,154,221	£3,605,171	36	Clinical Development of an Adoptive T cell Therapy for Triple Negative Breast Cancer	
Late	Manus Neurodynamica Ltd	North Shields, Tyne and Wear	£177,605	£254,499	24	Developing a novel non-invasive aid for early diagnosis of Parkinson's Disease	Northumbria NHS Foundation Trust
Late	Professor John Isaacs - Newcastle University	Newcastle upon Tyne	£1,029,567	£1,577,897	42	MICA: Targeting the RA synovial fibroblast via cyclin dependent kinase inhibition - a phase IIa study	
Late	Professor Guido Franzoso - Imperial College London	London	£4,109,700	£4,109,700	67	Treating Multiple Myeloma by Targeting the NF-Kappa-B Pathway with Gadd45-Beta/MKK7 Inhibitors	

Round 3b

Award Type	Lead Organisation	Location	Grant Value (£) *	Project Value (£) **	Project Duration (months)	Project Title	Additional grant awardees (SME-led awards only)
Early	Professor Garry Taylor - University of St Andrews	St Andrews	£335,731	£335,731	12	Multivalent proteins for the prophylaxis of influenza	
Early	Professor Hubert Gaspar - University College London	London	£681,305	£681,305	36	Development of a lentiviral gene therapy vector for treatment of haemophagocytic lymphohistiocytosis (HLH) due to perforin deficiency	
Early	Professor Sarah Tabrizi - University College London	London	£1,056,075	£1,056,075	40	Improving function in Huntington's disease through neurofeedback: using real-time fMRI to enhance cortical plasticity in early stages of the disease	
Early	Professor David Nutt - Imperial College London	London	£627,387	£1,161,387	36	MICA: [11C]BU99008 - A novel Positron Emission Tomography ligand for the Imidazoline2 Binding Site, First in human and initial patient group	
Early	Professor Christopher Cooper - University of Essex	Colchester	£1,013,404	£1,013,404	36	Engineering a new generation of blood substitutes	
Early	Professor Trevor Sharp - University of Oxford	Oxford	£897,299	£897,299	48	A novel lithium-mimetic drug for the management of impulse control disorder	
Early	Professor Christopher Mcgregor - University College London	London	£511,278	£511,278	24	Development of a Gal-free Calcification Resistant Porcine Pericardial Heart Valve.	
Early	Professor Matthias Koepf - University College London	London	£1,340,320	£1,911,320	48	MICA: Detecting ictogenicity and epileptogenesis	
Late	Prof Paresh Vyas - University of Oxford	Oxford	£497,286	£497,286	48	Clinical Investigation of a Humanized Anti-CD47 Antibody in Targeting Cancer Stem Cells in Acute Myeloid Leukaemia (and Solid Tumours).	
Late	Professor Stephen Bloom - Imperial College London	London	£3,953,796	£3,953,796	36	Next generation Y analogue for treatment of obesity	
Late	Dr Liudi Jiang - University of Southampton	Southampton	£428,803	£1,059,803.14	24	MICA: Integrated interfacial sensors for assessments of lower limb prosthetics	
Late	Dr Amit Nathwani - University College London	London	£1,598,000	£3,197,999.56	48	MICA: An open label dose-escalation study of a novel adeno associated viral vector for gene transfer in subjects with haemophilia A	Biomarin Pharmaceutical
Late	Exploristics Ltd	Ballynahinch, NI	£328,324	£547,206	36	New software to optimise the design of Stratified Medicine and Benefit-Risk studies	

Late	GeneFirst Ltd	Oxford	£495,508	£932,042	24	Finalise the development of a novel HPV test technology through clinical study	University of Edinburgh
------	---------------	--------	----------	----------	----	--	-------------------------

Round 4

Award Type	Lead Organisation	Location	Grant Value (£) *	Project Value (£) **	Project Duration (months)	Project Title	Additional grant awardees (SME-led awards only)
Feasibility (Confidence in Concept)	University of Birmingham	Birmingham	£600,000	£600,000	18	EXPERTISE: Expanding Interdisciplinary Translational Project Infrastructure	
Feasibility (Confidence in Concept)	University of Bath	Bath	£250,000	£250,000	18	University of Bath's MRC Confidence in Concept award	
Feasibility (Confidence in Concept)	University of Cambridge	Cambridge	£600,000	£600,000	18	Cambridge Confidence in Concepts: translating pathophysiological insights for patient benefit	
Feasibility (Confidence in Concept)	Cardiff University	Cardiff	£300,000	£300,000	18	Accelerating translation through strategic investment in Cardiff University's clinical innovation environment	
Feasibility (Confidence in Concept)	University of Dundee	Dundee	£800,000	£800,000	18	The Innovative Targets Portfolio: Basic Life Sciences Research to Novel Therapies, through a Portfolio of Small Molecule Translational Projects	
Feasibility (Confidence in Concept)	University of Edinburgh	Edinburgh	£500,000	£500,000	18	Edinburgh Translation of Medical Informatics	
Feasibility (Confidence in Concept)	University of Glasgow	Glasgow	£500,000	£500,000	18	Priming Innovative Translational Research - The University of Glasgow CiC Programme	
Feasibility (Confidence in Concept)	Imperial College London	London	£700,000	£700,000	18	Imperial Confidence in Concept Scheme (ICIC2)	
Feasibility (Confidence in Concept)	King's College London	London	£500,000	£500,000	18	Rapid and flexible support for translational research at King's Health Partners	
Feasibility (Confidence in Concept)	University of Leeds	Leeds	£300,000	£300,000	18	Delivering Value and Impact from Translating Leeds' Biomedical and Health Research	
Feasibility (Confidence in Concept)	University of Leicester	Leicester	£250,000	£250,000	18	Promoting early phase translational research through the Centre for Translational Therapeutics at the University of Leicester	
Feasibility (Confidence in Concept)	University of Liverpool	Liverpool	£400,000	£400,000	18	Bridging and accelerating the translation of novel scientific findings for health and wealth gain	
Feasibility (Confidence in Concept)	Liverpool School of Tropical Medicine	Liverpool	£500,000	£500,000	18	Tropical Infectious Disease Consortium: Expanding and Accelerating Product Development	

Feasibility (Confidence in Concept)	The University of Manchester	Manchester	£700,000	£700,000	18	The University of Manchester bid for phase II of MRC Confidence in Concept funding
Feasibility (Confidence in Concept)	Newcastle University	Newcastle	£500,000	£500,000	18	Newcastle University Confidence in Concept 2013
Feasibility (Confidence in Concept)	University of Nottingham	Nottingham	£600,000	£600,000	18	Translating Nottingham's discovery science research concepts: Biomedical Imaging; Diagnostics & Biomarkers; Drug Discovery, Development & Delivery
Feasibility (Confidence in Concept)	University of Oxford	Oxford	£600,000	£600,000	18	The Oxford MRC Confidence in Concept Partnership (CiCP): building on learnings and success from previous award.
Feasibility (Confidence in Concept)	Queen Mary, University of London	London	£250,000	£250,000	18	Target Validation Fund for in depth characterisation of novel targets in strategic disease areas
Feasibility (Confidence in Concept)	Queen's University Belfast	Belfast	£300,000	£300,000	18	Leveraging MRC Confidence In Concept funding to optimise and accelerate strategically important translational projects of high clinical and commercial potential
Feasibility (Confidence in Concept)	University of Sheffield	Sheffield	£360,000	£360,000	18	Addressing the funding gap to advance early stage healthcare research at the University of Sheffield
Feasibility (Confidence in Concept)	University of Strathclyde	Glasgow	£300,000	£300,000	18	Maximising Translational Durability II: Drug Discovery & In Vitro Diagnostics
Feasibility (Confidence in Concept)	University College London	London	£700,000	£700,000	18	The MRC Confidence in Concepts at UCL Fund 2013
Early	Professor Matthew Wood - University of Oxford	Oxford	£1,008,202	£1,008,202	36	Peptide conjugated oligonucleotides for splice switching therapy of Spinal Muscular Atrophy
Early	Dr Celia Morgan - University of Exeter	Exeter	£604,099	£604,099	35	Reducing relapse in alcohol dependence with the NMDA receptor antagonist, ketamine
Early	Dr Thomas Marchant - Christie Hospital NHS Trust	Manchester	£284,199	£284,199	36	Making cone beam CT imaging fit for aggressive targeting & adaptive re-planning of photon and proton radiotherapy
Early	Dr Sophia Karagiannis - King's College London	London	£964,727	£964,727	48	Preclinical efficacy of an antibody of the IgE class against a melanoma-associated antigen
Early	Professor John Collinge - University College London	London	£992,957	£1,268,956.74	24	MICA: Development of a small molecule therapeutic for the treatment of prion infection of humans
Early	OxSonics Limited		£2,124,283	£3,540,472	36	Enhancement and Mapping of Oncological Drug Delivery by Ultrasound
Early	Phico Therapeutics Ltd		£965,008	£1,608,346	18	Development of a novel antibacterial agent against Pseudomonas aeruginosa



Early	Xention Ltd		£1,456,900	£2,428,166	21	Development of a novel IKACH inhibitor for the treatment of atrial fibrillation	
Early	Nanoco Technologies Ltd		£307,898	£878,325	33	Cadmium-free quantum dots for cancer diagnostics using fluorescence imaging	University College London
Late	Dr Allan Lawrie - University of Sheffield	Sheffield	£516,152	£1,268,152	24	MICA: Developing novel human antibodies targeting the OPG/TRAIL axis for the treatment of pulmonary arterial hypertension (PAH)	
Late	Professor Alasdair MacLulich - University of Edinburgh	Edinburgh	£815,504	£911,504	30	MICA: Development of a software application for detection and monitoring of attentional deficits in delirium	
Late	Ziarco Pharma Ltd	Canterbury	£1,701,527	£2,835,878	21	PoC clinical study of ZPL-3893787 on pruritus and inflammation in atopic dermatitis	
Late	Oxford BioMedica (UK) Ltd	Oxford	£2,213,221	£3,688,702	36	Clinical Development of OXB-102	
Late	Autifony Therapeutics Limited	London	£1,619,669	£2,699,447	24	Clinical proof of concept trial of a Kv3 modulator for the treatment of tinnitus	University of Nottingham
Late	Levicept Ltd	Sandwich	£2,400,000	£11,855,208	30	p75NTR-Fc: a novel and safe biological for the treatment of chronic pain	
Late	Calcivis Ltd	Edinburgh	£297,000	£495,000	21	Clinical evaluation of advanced prototype medical device for dental caries assessment	
Late	MGB Biopharma Limited	Glasgow	£1,319,669	£2,197,449	18	Phase I study to assess tolerability, safety and PK of MGB-BP-3 in healthy volunteers	

Round 5

Award Type	Lead Organisation	Location	Grant Value (£) *	Project Value (£) **	Project Duration (months)	Project Title	Additional grant awardees (SME-led awards only)
Feasibility	XstalBio Ltd	Glasgow	£142,938	£190,584	12	Tablet Vaccines	
Feasibility	Plasticell Ltd.	Stevenage	£149,796	£199,728	12	Optimisation of human iPS cell-derived platelet manufacture	
Feasibility	Biosignatures Limited	Newcastle	£149,744	£199,659	12	Computer enhancement of clinical imaging	
Feasibility	Tecrea Ltd	London	£173,460	£198,393	12	Modulating intracellular oncology targets using Adhiron <sup>TM</sup> – a novel therapeutic approach	
Feasibility	CellCap Technologies Limited	Liverpool	£105,207	£120,283	12	A blood test for Alzheimer's disease - diagnosis and monitoring.	
Feasibility	Xention Limited	Pampisford, Cambridge	£144,795	£193,060	12	Development of a translational model system of the spinal pain synapse	
Feasibility	Pharmacogenomic Innovative Solutions Limited	High Wycombe	£60,844	£81,126	5	Novel Drug Targets for Treating Rheumatoid Arthritis based on Analysis of Human Genetic Data	
Feasibility	Cambimune	Fulbourn, Cambridge	£114,989	£153,318	12	Feasibility of site- directed delivery of endolysins for targeted antibacterial therapy	
Feasibility	Zilico Ltd	Manchester	£102,692	£136,924	7	Electrical Impedance Spectroscopy to detect neoplastic oral lesions	
Feasibility	PolyPhotonix Ltd	Sedgefield	£165,000	£200,000	12	the manufacture of a flexible blanket that will provide phototherapy treatment for a number of conditions (BAMBOO)	
Feasibility	MediWise	London	£170,130	£199,806	12	Non-invasive glucose monitoring using high-frequency radio waves	
Feasibility	Orphidia Ltd	London	£137,784	£183,712	9	HAITI-POC - High Accuracy Immunoassay Test at Point-of-Care	
Feasibility	Food Dudes Health Ltd	Knutsford	£148,767	£198,357	12	Behaviour Change e-Health Platform for Increasing Physical Activity in Children	

Feasibility	Vasgen Limited	London	£173,434	£199,996	12	Evaluating Novel Monoclonal Antibodies to Target ADAM15 for a Potential Novel Ocular Anti-Angiogenesis Therapy	
Feasibility	Biosceptre (UK) Ltd	Babraham, Cambridge	£149,985	£199,985	12	Novel therapeutic antibodies against nf-P2X7	
Feasibility	ProteinLogic Limited	Cambridge	£127,564	£166,919	7	Technical and Commercial Feasibility of a blood test for prediction of response to interferon treatment in Chronic Hepatitis B patients	
Feasibility	MISSION Therapeutics Ltd	Babraham, Cambridge	£149,620	£199,493	12	Feasibility of inhibiting desumoylating enzymes for treating platinum-resistant cancers	
Feasibility	Neuro 360 Ltd	London	£140,332	£187,109	6	Feasibility assessment of the opportunity for the use of transcranial cranial stimulation for the treatment of brain disorders	
Feasibility	Hypha Discovery	Uxbridge	£127,537	£170,049	11	Microbial Enzymatic Drug Modification to Improve Treatment Outcomes	
Feasibility	SmartAcoustics	Oxford	£146,810	£195,747	12	UbiquiSon - Ubiquitous ultrasound: machines within the reach of every clinician, all the time.	
Feasibility	GeneFirst Ltd	Oxford	£150,000	£200,000	12	Improved next generation sequencing to detect ultra-rare, cancer gene mutations in circulating cell-free DNA in blood	
Feasibility	Highland Biosciences Ltd	Inverness	£149,528	£199,371	12	Demonstrating Feasibility of a Novel Diagnostic for Thrombosis Risk	
Feasibility	C4X Discovery Limited	Manchester	£148,293	£197,724	12	Small-molecule agonists of GLP-1R for the treatment of Type-2 diabetes	
Early	Dagmar Scheel-Toellner - University of Birmingham	Birmingham	£472,338	£472,338	36	Specific targeting of a pro-inflammatory B cell subset in rheumatoid arthritis	
Early	Andrew Pollard - University of Oxford	Oxford	£1,245,597	£1,245,597	44	A novel vaccine for broad protection against meningococcal disease: progression to phase 1 clinical trial	
Early	Matthew Wood - University of Oxford	Oxford	£1,008,107	£1,008,107	36	Exosome-based Gene Therapy for Huntington's Disease	
Early	Sensium Healthcare	Abingdon	£337,663	£496,804	12	A wireless, wearable, automated early warning system for patients in emergency care	University of Leicester
Early	SIRAKOSS	Edinburgh	£939,895	£1,566,492	30	Production and pre-clinical testing of MaxSi™ Graft synthetic bone graft substitutes	
Early	Domainex Ltd	Cambridge	£1,396,644	£2,327,742	27	Development of a new treatment for Chronic Obstructive Pulmonary Disease	

Late	Professor Stuart Forbes - University of Edinburgh	Edinburgh	£3,065,647	£3,065,647	60	Autologous Macrophage Therapy for Liver Cirrhosis	
Late	Dr Sarah Cartmell - The University of Manchester	Manchester	£1,221,230	£1,221,230	32	Novel tendon attachment and repair strategy	
Late	HeartLight Systems Ltd	Derby	£1,415,727	£1,807,467	30	HeartLight: Heart-Rate Monitoring for Neonatal Resuscitation	Tioga; University of Nottingham
Late	XO1 Ltd	Babraham, Cambridge	£1,103,209	£1,838,682	34	Evaluation of an antibody that inhibits thrombosis without causing bleeding	
Late	Modern Biosciences plc	London	£2,400,000	£5,008,200	36	Novel, oral bone-protecting compounds for the treatment of rheumatoid arthritis	
Late	Kimal plc	Bromsgrove	£267,788	£446,314	12	Demonstration of a Sensor Catheter Technology for the Real Time Diagnosis of Sepsis	
Late	F2G Ltd	Manchester	£1,369,632	£2,282,720	17	Phase I oral safety assessment of a novel antifungal for systemic fungal infections	
Late	Xstrahl Ltd	Camberley, Surrey	£668,126	£1,016,222	12	Clinical Assesment of Compact Gamma Camera: An advancement in cancer diagnosis	University of Nottingham

Round 6

Award Type	Lead Organisation	Location	Grant Value (£) *	Project Value (£) **	Project Duration (months)	Project Title	Additional grant awardees (SME-led awards only)
Early	Richard Ross - University of Sheffield	Sheffield	£2,401,085	£2,401,085	36	Development of a long-acting growth hormone antagonist to address the unmet need for treatment in acromegaly	
Early	Lindy Durrant - University of Nottingham	Nottingham	£847,163	£847,163	36	Improving the functional affinity of human anti-glycan monoclonal antibodies (mabs) for cancer therapy	
Early	Hemant M Kocher - Queen Mary, University of London	London	£583,942	£1,217,942	36	MICA: Early phase clinical trial repurposing ATRA as stromal targeting agent in a novel drug combination for pancreatic cancer (STAR-PAC)	
Early	Yaohe Wang - Queen Mary, University of London	London	£495,166	£495,166	24	Development of an effective therapeutic regime for preventing cancer recurrence after surgery using a novel viro-immunotherapeutic agent	
Early	Robin J Shattock - Imperial College London	London	£939,055	£1,076,478	30	MICA: Ad4HIV, A Phase I Trial Investigating Ad4, MVA and Protein Immunisation Strategies to Maximise Protective Antibody Responses to HIV-1 Envelope	
Early	Michael Murphy - University of Cambridge	Cambridge	£689,544	£689,544	28	Selective S-nitrosation of mitochondrial complex I by MitoSNO as a new therapy for cardiac ischaemia-reperfusion injury	
Early	Laura Kenny - Imperial College London	London	£745,419	£1,060,419	36	Molecular imaging of HER2 receptor expression using PET: mechanistic study of the novel [18F]-HER2-Affibody tracer in metastatic breast cancer	
Early	Xiros Ltd	Leeds	£767,186	£1,278,644	24	Pharmacologically active, haemostatic fibres and devices	Haemostatix
Early	Anacail Ltd	Glasgow	£294,447	£430,000	18	Ozone destruction of biofilms for high level decontamination in healthcare	University of Glasgow
Early	PhoreMost Ltd	Widdington, Essex	£1,386,133	£2,310,222	18	Targeting KRAS mutant cancers using a novel inhibitor of PLK1 substrate binding	
Early	Heptares Therapeutics Ltd	Welwyn Garden City	£1,504,140	£2,391,370	36	Pre-clinical development of a novel oral therapy for hyperinsulinemic hypoglycaemia	The University of Manchester
Late	University College London	London	£2,282,063	£2,282,063	60	MSCTRAIL for lung cancer	
Late	Ingenza Ltd	Roslin, Midlothian	£829,336	£1,038,584	36	A novel enzymatic means to confirm correct and safe nasogastric tube placement	Imperial College London

Late	Haemair Ltd	Swansea	£1,212,846	£2,021,410	36	Design for manufacture of an innovative Extra Corporeal Membrane Oxygenator	
Late	Oxtex Ltd	Oxford	£300,749	£501,248	30	Self-Expanding Hydrogel Soft Tissue Generator	

Round 7

Award Type	Lead Organisation	Location	Grant Value (£) *	Project Value (£) **	Project Duration (months)	Project Title	Additional grant awardees (SME-led awards only)
Feasibility (Confidence in Concept)	University of Dundee	Dundee	£700,000	£700,000	18	The Innovative Targets Portfolio: Basic Life Sciences Research to Novel Therapies, through a Portfolio of Small Molecule Translational Projects	
Feasibility (Confidence in Concept)	Imperial College London	London	£800,000	£800,000	18	Imperial Confidence in Concept: ICiC3	
Feasibility (Confidence in Concept)	Newcastle University	Newcastle	£600,000	£600,000	18	Newcastle University Confidence in Concept 2014	
Feasibility (Confidence in Concept)	University of Nottingham	Nottingham	£600,000	£600,000	18	Establishing the potential for healthcare benefits arising from novel biomedical research concepts and discoveries at The University of Nottingham	
Feasibility (Confidence in Concept)	University of Oxford	Oxford	£650,000	£650,000	18	Accelerating discovery science to clinical translation: CiC3 - The Oxford MRC CiC Pipeline	
Feasibility (Confidence in Concept)	University of Edinburgh	Edinburgh	£700,000	£700,000	18	Confidence in Concept CMVM University of Edinburgh Edinburgh Partners in Translation (EPiT)	Heriot-Watt University
Feasibility (Confidence in Concept)	King's College London	London	£650,000	£650,000	18	King's Health Partners Confidence in Concept	
Feasibility (Confidence in Concept)	University of Bath	Bath	£250,000	£250,000	18	University of Bath's MRC Confidence in Concept award	
Feasibility (Confidence in Concept)	University of Birmingham	Birmingham	£600,000	£600,000	18	University of Birmingham MRC Confidence in Concept 2014: Open Innovation Through Local Integration	
Feasibility (Confidence in Concept)	Cardiff University	Cardiff	£300,000	£300,000	18	Accelerating translational research through Cardiff University's Clinical Innovation pipeline	
Feasibility (Confidence in Concept)	University of Leeds	Leeds	£400,000	£400,000	18	Maximising patient benefit: Leeds' Interdisciplinary approach to translation	
Feasibility (Confidence in Concept)	University of Liverpool	Liverpool	£300,000	£300,000	18	University of Liverpool Confidence in Concept Program – Enhancing Translation	
Feasibility (Confidence in Concept)	Liverpool School of Tropical Medicine	Liverpool	£500,000	£500,000	18	Tropical Infectious Disease Consortium: Sustaining, Expanding and Accelerating Product Development	

Feasibility (Confidence in Concept)	The University of Manchester	Manchester	£700,000	£700,000	18	The University of Manchester (UoM) bid for phase III of MRC Confidence in Concept funding
Feasibility (Confidence in Concept)	Queen's University Belfast	Belfast	£300,000	£300,000	18	Application of drug delivery technologies to enhance translational of experimental therapeutics
Feasibility (Confidence in Concept)	University of Aberdeen	Aberdeen	£200,000	£200,000	18	The Aberdeen Translational Accelerator Fund: bridging biomedical innovation and translational impact
Feasibility (Confidence in Concept)	University of Sheffield	Sheffield	£360,000	£360,000	18	Addressing the funding gap to advance early stage healthcare research at the University of Sheffield
Feasibility (Confidence in Concept)	University of Cambridge	Cambridge	£600,000	£600,000	18	Cambridge Confidence in Concepts: translating pathophysiological insights for patient benefit
Feasibility (Confidence in Concept)	University of Leicester	Leicester	£250,000	£250,000	18	Driving Translational Biomedical Research At The University Of Leicester
Feasibility (Confidence in Concept)	University College London	London	£700,000	£700,000	18	The MRC Confidence in Concepts at UCL Fund 2014
Early	John Maher - King's College London	London	£502,384	£502,384	24	Immunotherapy of Epithelial Ovarian Cancer using Autologous Gamma Delta T-cells
Early	Waljit Singh Dhillon - Imperial College London	London	£347,939	£347,939	27	MICA: Neurokinin 3 Receptor Antagonism as a Novel Treatment for Menopausal Hot Flashes
Early	Stephen Brian Gordon - Liverpool School of Tropical Medicine	Liverpool	£599,790	£629,790	21	P4-IVIG immunotherapy for adjunct treatment of severe respiratory infection
Early	Roger Gunn - Imperial College London	London	£204,400	£204,400	24	Repurposing Low-Cost Consumer Technology for Motion Correction in Dementia Neuroimaging
Early	Simon Arthur - University of Dundee	Dundee	£415,739	£415,739	24	Development of novel JAK3 inhibitors for the treatment of autoimmunity.
Early	Simon P MacKay - University of Strathclyde	Glasgow	£1,207,373	£1,207,373	24	First-in-class Selective IKKalpha Inhibitors for the Treatment of Castrate Resistant Prostate Cancer (CRPC) and Pancreatic Cancer
Early	Paul Nicholas Bishop - The University of Manchester	Manchester	£632,676	£632,676	24	Development of an opticin-based anti-angiogenic therapeutic for the treatment of ocular disease.
Early	Martin Drysdale - University of Glasgow	Glasgow	£1,553,594	£1,553,594	24	Targeting the Salt Inducible Kinase 2 (SIK2) for cancer therapy
Late	Robin Raihan Ali - University College London	London	£2,986,496	£2,986,496	60	Clinical trial of gene therapy for the treatment of Leber congenital amaurosis



Late	Christine Elaine Pullar - University of Leicester	Leicester	£1,934,403	£1,934,403	48	The development of topical salbutamol to prevent human skin scarring and hyperpigmentation	
Late	Shakeel Shahdad - Queen Mary, University of London	London	£356,185	£356,185	24	Preclinical Development of a Novel Bioactive Glass Cement for Bone Graft Substitution in Dentistry	
Late	Sebastian L Johnston - Imperial College London	London	£1,272,161	£1,307,161	27	Effect of CRTH2 Antagonist OC459 on Response to Rhinovirus Challenge in Asthma	
Late	John Kelly - University College London	London	£1,417,964	£1,417,964	36	Development of the UroMark assay. A non-invasive test for the detection of bladder cancer in urinary sediment cells	
Late	Autifony Therapeutics Ltd	London	£2,421,116	£3,267,555	24	Clinical Development of AUTO0206 for the treatment of schizophrenia	Kings College London; The University of Manchester; Newcastle University
Late	Momentum Bioscience	Cardiff	£1,233,535	£2,055,891	33	Rapid determination of negative blood cultures	
Late	eXmoor pharma concepts	Brompton Regis, Somerset	£1,166,536	£1,944,227	24	CPrep - Closed point of care preparation device (phase 2)	Amercare
Late	Vhsquared	Babraham, Cambridge	£1,257,012	£2,095,021	12	Reducing Risk on the clinical pathway to PoC for a novel oral biologic for IBD	
Late	KalVista Pharmaceuticals Ltd	Salisbury	£2,400,000	£6,753,351	36	Clinical development to PoC of a novel oral plasma kallikrein inhibitor for the treatment of diabetic macular edema (DME)	

Round 8

Award Type	Lead Organisation	Location	Grant Value (£) *	Project Value (£) **	Project Duration (months)	Project Title	Additional grant awardees (SME-led awards only)
Feasibility	Bioarchitech Ltd	Kindlington, Oxford	£135,870	£194,100	12	Development of novel oncolytic viruses for treatment of cancer	
Feasibility	RINICARE Limited	Lancaster	£161,758	£189,652	12	PREDICTOR Feasibility Study	The University of Manchester; Durham University
Feasibility	Cypralis Ltd	Ongar, Essex	£119,996	£199,994	10	Selective inhibitors of cyclophilin D for the treatment of acute pancreatitis	
Feasibility	BreathDX (UK) Limited	Bristol	£169,040	£200,000	12	New breath diagnostics to improve management of hyperammonaemic acidaemias	University of the West of England; Birmingham Children's Hospital
Feasibility	Medical Wireless Sensing Ltd. (MediWise)	London	£164,732	£199,529	12	Skin-Agnostic Non-Invasive Blood Glucose Monitoring	King's College London
Feasibility	Domainex Limited	Cambridge	£139,883	£199,833	12	NSD inhibitors for the treatment of multiple myeloma and other cancers□	
Feasibility	Eva Diagnostics Limited	London	£139,855	£199,793	12	Comprehensive blood counts in a handheld device	
Feasibility	3D Engineering Design Limited	Nottingham	£139,927	£199,897	12	An innovative inhaler for improved asthma management	
Feasibility	Crescendo Biologics Ltd	Cambridge	£137,605	£197,605	12	Next generation ADC therapeutics: Improved potency & safety for treating cancer	
Feasibility	Sareum Ltd	Pampisford, Cambridge	£139,755	£199,650	12	Studies to validate novel inhibitors of TYK2 kinase as anti-cancer therapeutics	
Feasibility	Critical Pharmaceuticals Ltd	Nottingham	£139,923	£199,890	12	Sustained Release Bevasizumab for the Treatment of AMD	
Feasibility	Peptinnovate Limited	Stevenage	£139,996	£199,996	12	MoA studies of molecules derived from TB bacteria for the treatment of asthma	
Feasibility	NuVision Ophthalmics Ltd	Nottingham	£105,721	£151,030	12	Omnigen: Novel Stem Cell Treatment for Acute Ocular Surface Trauma	

Early	Sarah Catherine Gilbert - University of Oxford	Oxford	£677,290	£677,290	24	Pre-clinical development of an influenza vaccine to induce broad protection through multiple immune mechanisms	
Early	Andrew Jenkins - University of Bath	Bath	£900,898	£1,063,898	36	Development of an infection detecting wound dressing	
Early	Trevor Yeung - University of Oxford	Oxford	£634,024	£634,024	36	Investigating the use of fluorescent proteins to identify dysplasia during endoscopy and surgery	
Early	John Richard Atack - University of Sussex	Brighton	£1,777,756	£1,797,756	24	MICA: Valium without the sedation: Non-sedating anxiolytic GABAA receptor modulators for the treatment of anxiety disorders.	
Early	Tim Cheetham - Newcastle University	Newcastle	£780,643	£780,643	52	Adjuvant Rituximab - a potential cure for the young patient with Graves' hyperthyroidism	
Early	Cytosystems Limited	Aberdeen	£495,205	£688,849	18	Stratification of patients with bladder cancer for cystoscopic surveillance	University of St Andrews
Early	Brainomix Limited	Oxford	£633,553	£1,055,922	24	Imaging software to quantify salvageable brain tissue to select stroke patients	
Early	MISSION Therapeutics	Babraham, Cambridge	£1,892,918	£3,154,863	24	Development of USP7 inhibitors for cancer therapy	
Early	Sentinel Oncology Limited	Cambridge	£943,160	£1,571,933	18	Development of a new drug for the treatment of Autism caused by Fragile X Syndrome	
Early	Ohmedics Ltd	Glasgow	£759,274	£1,052,107	36	Lung infection monitor for chronic disease patients	University of Strathclyde
Late	Stephen Edward Moss - University College London	London	£5,501,648	£5,501,648	66	A Phase I/IIa Clinical Trial of a Humanised Monoclonal Antibody Against LRG1	
Late	Graham Michael Lord - King's College London	London	£2,908,102	£3,287,102	60	MICA: Targeted Regulatory T Cell Therapy for Inflammatory Bowel Disease	

\* Conditional offers subject to confirmatory checks

\*\*Excludes university contribution to Full Economic Costing (FEC) on academic-only projects